Synaptogenix (NASDAQ:TAOX) Trading Down 5.2% – Should You Sell?

Synaptogenix, Inc. (NASDAQ:TAOX)’s stock price was down 5.2% on Monday . The stock traded as low as $4.82 and last traded at $4.92. Approximately 116,195 shares were traded during trading, a decline of 40% from the average daily volume of 194,545 shares. The stock had previously closed at $5.19.

Analysts Set New Price Targets

Several brokerages have recently issued reports on TAOX. Wall Street Zen lowered shares of Synaptogenix from a “hold” rating to a “sell” rating in a research note on Saturday, April 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Synaptogenix in a research note on Tuesday, April 21st. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Synaptogenix Price Performance

The business has a 50 day moving average of $4.99 and a 200 day moving average of $5.65. The firm has a market capitalization of $36.76 million, a price-to-earnings ratio of -0.29 and a beta of 1.68.

Synaptogenix (NASDAQ:TAOX) last released its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. The company had revenue of ($2.46) million during the quarter.

About Synaptogenix

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University.